News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Hedge Fund Wants Actelion Ltd. CEO To Quit
February 4, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
(Reuters) - Actelion (ATLN.VX) shares rose 3.5 percent on Friday after hedge fund shareholder Elliott Advisors called for its chairman and chief executive to resign from the board in a push for a sale of the Swiss biotech firm.
Twitter
LinkedIn
Facebook
Email
Print
People
MORE ON THIS TOPIC
Cancer
GSK Cuts Five-Year-Old Cancer Collaboration With Ideaya
December 8, 2025
·
2 min read
·
Tristan Manalac
Collaboration
Crescent, Kelun-Biotech Swap Therapies in ADC-Bispecific Deal Worth Up To $1.25B
December 4, 2025
·
2 min read
·
Tristan Manalac
Opinion
Even Early Stage Biotechs Can’t Ignore Tariffs
December 3, 2025
·
4 min read
·
Josh Medow
Venture capital
Lilly, Novo GLP-1 Pricing Plans Clear Runway For Future Competitors
December 3, 2025
·
2 min read
·
Annalee Armstrong
